STRATEGIC USE OF PHARMACOECONOMIC RESEARCH IN EARLY DRUG DEVELOPMENT AND GLOBAL PRICING

[1] Bootman J.L., Larson L.N., McGhan W.F., Townsend R.J., Pharmacoeconomic research and clinical trials: concepts and issues, Drug Intelligence and Clinical Pharmacy, 23, pp. 693-697, (1989)

[2] Burstall M.L., Europe aftcr 1992: implications for pharmaceuticals, Health Affairs, 10, 3, pp. 151-171, (1991)

[3] Chrischillcs E.A., The contributions of epidemiology to pharmacoeconomic research, Drug Information Journal, 26, pp. 219-229, (1992)

[4] Detsky A., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, pp. 354-361, (1993)

[5] Di Masi J.A., Hansen R.W., Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10, pp. 235-238, (1991)

[6] Drummond M., Cost-of-illness studies: a major headache?, PharmacoEconomics, 2, pp. 1-4, (1992)

[7] Drummond M.F., Teeling-Smilh G., Wells N., Economic evluation in the development of medicincs, (1988)

[8] Eddy D.M., What’s going on in Oregon?, Journal of the American Medical Associalion, 266, 3, pp. 417-420, (1991)

[9] Eddy J.M., Oregon’s methods: did cosl-effectiveness analysis fail?, Journal of the American Medical Association, 266, 15, pp. 2135-2141, (1991)

[10] Fulda T.R., Hass S.L., Medicaid drug utilisation review under OBRA 1990: current issues and future directions, PharmacoEconomics, 2, pp. 363-370, (1993)

[1] Bootman J.L., Larson L.N., McGhan W.F., Townsend R.J., Pharmacoeconomic research and clinical trials: concepts and issues, Drug Intelligence and Clinical Pharmacy, 23, pp. 693-697, (1989)

[2] Burstall M.L., Europe aftcr 1992: implications for pharmaceuticals, Health Affairs, 10, 3, pp. 151-171, (1991)

[3] Chrischillcs E.A., The contributions of epidemiology to pharmacoeconomic research, Drug Information Journal, 26, pp. 219-229, (1992)

[4] Detsky A., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, pp. 354-361, (1993)

[5] Di Masi J.A., Hansen R.W., Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10, pp. 235-238, (1991)

[6] Drummond M., Cost-of-illness studies: a major headache?, PharmacoEconomics, 2, pp. 1-4, (1992)

[7] Drummond M.F., Teeling-Smilh G., Wells N., Economic evluation in the development of medicincs, (1988)

[8] Eddy D.M., What’s going on in Oregon?, Journal of the American Medical Associalion, 266, 3, pp. 417-420, (1991)

[9] Eddy J.M., Oregon’s methods: did cosl-effectiveness analysis fail?, Journal of the American Medical Association, 266, 15, pp. 2135-2141, (1991)

[10] Fulda T.R., Hass S.L., Medicaid drug utilisation review under OBRA 1990: current issues and future directions, PharmacoEconomics, 2, pp. 363-370, (1993)